Clinical trial NCT04768985: Study to Assess the Bioequivalence of Acalabrutinib Tablet and Acalabrutinib Capsule
Official title: A Phase I, Open-Label, Randomized, 2-Treatment, 2-Period, Crossover Study in Healthy Subjects to Assess the Bioequivalence of Acalabrutinib Tablet and Acalabrutinib Capsule
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE1
Conditions: Bioequivalence
Keywords: Pharmacokinetics
Healthy participants
Bruton tyrosine kinase
Acalabrutinib
Lead sponsor: AstraZeneca
Sponsor class: INDUSTRY
First posted: 2021-02-24
Enrollment: 66
Sex: ALL
Minimum age (years): 18
Maximum age (years): 55
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: CROSSOVER
Primary purpose: OTHER

Brief summary: This study is a multicenter, Phase I, open-label, randomized, 2-sequence, 2-treatment, 2-period, crossover, bioequivalence study with single doses of acalabrutinib administered orally in healthy participants. The study is designed to demonstrate the bioequivalence of acalabrutinib tablet (Treatment A) compared with marketed acalabrutinib capsule (Treatment B) in the fasted state.

Detailed description: Eligible healthy participants will be randomized to receive either treatment sequence 1 (AB) or treatment sequence 2 (BA), as follows:

* Treatment A: Acalabrutinib tablet, 100 mg, fasted state
* Treatment B: Acalabrutinib capsule, 100 mg, fasted state

Participants will receive fixed single doses of acalabrutinib on 2 occasions, under fasted conditions.

The study will comprise:

* Visit 1: A screening period of up to 28 days before first dosing.
* Visit 2: Two treatment periods:

  * Participants will be admitted to the study center on Day -2 of Treatment Period 1 to confirm eligibility before first dosing. Eligibility criteria will be reconfirmed on Day -1 of each treatment period.
  * On Day 1 of Treatment Periods 1 and 2, participants will be administered the assigned treatment (A or B) as randomized, followed by a protocol defined washout period between Treatment Periods 1 and 2.
* Visit 3: A Follow-up Visit/Early Termination Visit at 7 to 10 days after last administration of study drug.

Each participant will be involved in the study for approximately 6 weeks.

Eligibility criteria: Inclusion Criteria:

* Females must have a negative pregnancy test at Screening and on admission to the study center, must not be lactating, and must be of non-childbearing potential, confirmed at Screening, by fulfilling protocol defined criteria
* Have a body mass index between 18.5 and 30 kg/m\^2 inclusive and weigh at least 50 kg and no more than 100 kg inclusive, at Screening
* Non-smokers and those participants who have not smoked (including e cigarettes) or used nicotine products (cigarettes, pipes, cigars, chewing tobacco, nicotine patch, or any other nicotine containing products) within the 90 days prior to Screening
* Calculated creatinine clearance (CrCl) ≥ 90 mL/min as determined by Cockcroft-Gault method (using actual body weight)

Males:

CrCl = Weight (kg) × (140 - Age)/72 × serum creatinine (mg/dL) in mL/min

Females:

CrCl = Weight (kg) × (140 - Age) × 0.85/72 × serum creatinine (mg/dL) in (mL/min)

Exclusion Criteria:

* History or presence of any clinically significant disease (including active coronavirus disease 2019 \[COVID-19\] infection) or disorder
* History or presence of gastrointestinal, hepatic, or renal disease, or any other condition known to interfere with absorption, distribution, metabolism, or excretion of drugs
* Any clinically significant illness, medical/surgical procedure, or trauma within 30 days of the first administration of study drug
* Any clinically significant abnormalities in hematology, coagulation, clinical chemistry, or urinalysis results, at Screening and prior to first dose, as judged by the Investigator and defined as:

  (i) Hemoglobin less than lower limit of normal (ii) Absolute neutrophils less than lower limit of normal (iii) Platelets less than lower limit of normal (iv) Serum alanine aminotransferase, aspartate aminotransferase, alkaline phosphatase or serum bilirubin (total bilirubin and direct bilirubin) \> upper limit of normal
* Any clinically significant abnormal findings in vital signs at Screening or on Day 1 (eg, systolic BP \< 90 mmHg or \> 140 mmHg; diastolic BP \< 50 mmHg or \> 90 mmHg; pulse \< 45 or \> 90 bpm)
* Any clinically significant abnormalities on standard 12-lead ECG at Screening or on Day 1
* Any positive result for HBsAg, hepatitis C antibody, and HIV testing, at Screening
* Has received a new chemical entity (defined as a compound which has not been approved for marketing) within 90 days of the first administration of study drug in this study. The period of exclusion begins 90 days after the final dose or 30 days after the last visit whichever is the longest
* History of severe allergy/hypersensitivity or ongoing allergy/hypersensitivity, or history of hypersensitivity to drugs with a similar chemical structure or class to acalabrutinib
* Positive screen for drugs of abuse or cotinine and alcohol, at Screening and on admission to the study center
* Treatment with prescription or non-prescription drugs or other products known to be strong CYP3A, P-gp, or breast cancer resistance protein (BCRP) inhibitors or substrates of BCRP or MATE1 (within 14 days before first administration of study drug or longer if the medication has a long half life) and strong CYP3A inducers (within 28 days before first administration of study drug or longer if the medication has a long half life)
* Use of any prescribed or non prescribed medication including antacids, analgesics (other than paracetamol/acetaminophen), herbal remedies, megadose vitamins (intake of 20 to 600 times the recommended daily dose), and minerals during the 14 days prior to the first administration of study drug or longer if the medication has a long half life
* Excessive intake of caffeine-containing drinks or food (eg, coffee, tea, chocolate) as judged by the Investigator
* Inability to swallow acalabrutinib tablets or acalabrutinib capsules
* Evidence of ongoing systemic bacterial, fungal, or viral infection (including upper respiratory tract infections)
* Participant has a positive test result for severe acute respiratory syndrome coronavirus 2 reverse transcriptase polymerase chain reaction before randomization
* Participant has clinical signs and symptoms consistent with COVID-19, eg, fever, dry cough, dyspnea, sore throat, fatigue, or confirmed infection by appropriate laboratory test within the last 4 weeks prior to Screening or on admission
* History of severe COVID-19 (hospitalization, extracorporeal membrane oxygenation, mechanically ventilated)
* Participants who are regularly exposed to COVID-19 as part of their daily life (eg, health care professionals working in COVID-19 wards or at emergency departments)

Primary outcomes:
measure: Area under plasma concentration time curve from zero to infinity (AUCinf) of Acalabrutinib
timeFrame: Pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 5, 6, 8, 10, 12, 24, and 48 hours post-dose
measure: Area under the plasma concentration time curve from zero to the last quantifiable concentration (AUClast) of Acalabrutinib
timeFrame: Pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 5, 6, 8, 10, 12, 24, and 48 hours post-dose
measure: Maximum observed plasma (peak) drug concentration (Cmax) of Acalabrutinib
timeFrame: Pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 5, 6, 8, 10, 12, 24, and 48 hours post-dose
Secondary outcomes:
measure: Area under plasma concentration time curve from zero to infinity (AUCinf) of ACP-5862
timeFrame: Pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 5, 6, 8, 10, 12, 24, and 48 hours post-dose
measure: Area under the plasma concentration time curve from zero to the last quantifiable concentration (AUClast) of ACP-5862
timeFrame: Pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 5, 6, 8, 10, 12, 24, and 48 hours post-dose
measure: Maximum observed plasma (peak) drug concentration (Cmax) of ACP-5862
timeFrame: Pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 5, 6, 8, 10, 12, 24, and 48 hours post-dose
measure: Time to reach peak or maximum concentration (tmax) following drug administration for acalabrutinib and ACP-5862
timeFrame: Pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 5, 6, 8, 10, 12, 24, and 48 hours post-dose
measure: Half life associated with terminal slope (λz) of a semi logarithmic concentration time curve (t½λz) for acalabrutinib and ACP-5862
timeFrame: Pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 5, 6, 8, 10, 12, 24, and 48 hours post-dose
measure: Mean residence time of the unchanged drug in the systemic circulation from zero to infinity (MRT) for acalabrutinib and ACP-5862
timeFrame: Pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 5, 6, 8, 10, 12, 24, and 48 hours post-dose
measure: Terminal rate constant, estimated by log linear least squares regression of the terminal part of the concentration time curve (λz) for acalabrutinib and ACP-5862
timeFrame: Pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 5, 6, 8, 10, 12, 24, and 48 hours post-dose
measure: Metabolite (ACP-5862) to parent (acalabrutinib) ratio based on AUCinf and/or AUClast (M:P[AUC])
timeFrame: Pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 5, 6, 8, 10, 12, 24, and 48 hours post-dose
measure: Metabolite (ACP-5862) to parent (acalabrutinib) ratio based on Cmax (M:P [Cmax])
timeFrame: Pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 5, 6, 8, 10, 12, 24, and 48 hours post-dose
measure: Number of participants with adverse events and serious adverse events
timeFrame: From screening day (Day -28) until Follow-up/end of treatment visit (at 7 to 10 days after last study drug administration)
Other outcomes:
Locations:
city: Glendale
country: United States
facility: Research Site
state: California
city: Brooklyn
country: United States
facility: Research Site
state: Maryland
city: Salt Lake City
country: United States
facility: Research Site
state: Utah
Study officials:
affiliation: Parexel Early Phase Clinical Unit Baltimore Harbor Hospital 3001 South Hanover St. Baltimore, MD 21225 USA
name: Ronald Goldwater, MD
role: PRINCIPAL_INVESTIGATOR
References: